GU Cancers 2019 | PSMA ADC in prostate cancer: Phase I results

Daniel Petrylak

Prof. Daniel Petrylak, MD, from the Yale Cancer Center, New Haven, CT, presents results from a Phase I study, where chemotherapy-refractory prostate cancer patients were given prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in escalating doses. At the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Petrylak also speaks of the recently completed Phase II trial (NCT01695044), where patients with no prior chemotherapy were administered PSMA ADC, with the results still pending.

Share this video